Osteogenic potential and synergistic effects of growth factors delivered from a bionic composite system

Chen, Tao; Gomez, Alan W.; Zuo, Yi; Li, Xiang; Zhang, Zhen; Li, Yubao; Hu, Jing; Li, Jihua

doi:10.1002/jbm.a.35605

Cited by 6 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a preferable strategy for other GFs to accompany FGF in order to obtain a promising outcome. Chen et al (2016) chose gelatin microspheres as BMP-2 and basic FGF (bFGF) carriers, which were further embedded in a commercialized injectable thermal-sensitive hydrogel. The hydrogel was injected into a porous cell-loading scaffold before use.…”

Section: Fibroblast Growth Factor (Fgf)mentioning

confidence: 99%

Advancements in Hydrogel-Based Drug Sustained Release Systems for Bone Tissue Engineering

Zhang

Peng

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Bone defects caused by injury, disease, or congenital deformity remain a major health concern, and efficiently regenerating bone is a prominent clinical demand worldwide. However, bone regeneration is an intricate process that requires concerted participation of both cells and bioactive factors. Mimicking physiological bone healing procedures, the sustained release of bioactive molecules plays a vital role in creating an optimal osteogenic microenvironment and achieving promising bone repair outcomes. The utilization of biomaterial scaffolds can positively affect the osteogenesis process by integrating cells with bioactive factors in a proper way. A high water content, tunable physio-mechanical properties, and diverse synthetic strategies make hydrogels ideal cell carriers and controlled drug release reservoirs. Herein, we reviewed the current advancements in hydrogel-based drug sustained release systems that have delivered osteogenesisinducing peptides, nucleic acids, and other bioactive molecules in bone tissue engineering (BTE).

show abstract

Section: Fibroblast Growth Factor (Fgf)mentioning

confidence: 99%

Advancements in Hydrogel-Based Drug Sustained Release Systems for Bone Tissue Engineering

Zhang

Peng

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Various growth factors, osteogenic proteins, and modified small molecule active peptides have been designed and synthesized. Osteogenic‐related active factors include vascular endothelial growth factor (Huang, Kaigler, Rice, Krebsbach, & Mooney, ), basic fibroblast growth factor (Chen et al, ), platelet‐derived growth factors (Andrae, Gallini, & Betsholtz, ), insulin‐like growth factor (Rico‐Llanos, Becerra, & Visser, ). Osteogenic‐associated proteins consist of bone morphogenetic protein‐2 (BMP‐2; Sun et al, ; Zhan, Liu, & Yu, ), parathyroid hormone (PTH; Khundmiri, Murray, Lederer, & Vitamin, ), and enamel matrix protein derivative (Shahriari, Houshmand, Razavian, Khazaei, & Abbas, ).…”

Section: Introductionmentioning

confidence: 99%

Ectopic osteogenesis by type I collagen loaded with a novel synthesized PTH‐related peptide‐1 in vivo

Wang

Jian

et al. 2019

J Biomedical Materials Res

View full text Add to dashboard Cite

This study aims to investigate the ability of parathyroid hormone (PTH)-related peptide-1/type I collagen (PTHrP-1/Col-I) scaffold material to induce ectopic osteogenesis in the quadriceps muscle pocket of Sprague-Dawley (SD) rats. A novel peptide PTHrP-1 was derived from PTH and used at different concentrations (0, 0.1, 0.3, and 0.5 mg/ml) to induce ectopic osteogenesis. Radiographic examinations (X-ray, CT, and 3D reconstruction), pathological observations (H&E, Masson, Von Kossa, ALP and TRAP staining), immunohistochemical staining (Col-I, OCN and Runx-2 in tissues), western blotting was used to determine the qualitative and quantitative analysis of related markers proteins. Results confirmed that the appropriate concentration of PTHrP-1 can effectively enhance the osteogenic activity, thereby improving the positive results and protein expression of osteogenic markers (COL-I, OCN, and Runx-2) in the quadriceps muscle pocket of SD rats. Through qualitative and quantitative analysis, high concentration of PTHrP-1 promotes osteogenic activity and active bone resorp-tion. This study confirmed that PTHrP-1 is a novel small molecule bioactive peptide, and the rat tail collagen scaffold is a good carrier of PTHrP-1 with excellent biocompatibility. The PTHrP-1/Col-I composite scaffold material is an effective substitute for bone tissue engineering and can effectively induce and promote bone formation in the quadriceps muscle pocket of rats. In addition, the promoting ability for osteogenic differentiation of 0.3 mg/ml PTHrP-1/Col-I composite scaffold material group was significantly better than that of 0, 0.1 and 0.5 mg/ml PTHrP-1/Col-I composite scaffold material groups. Hence, the optimal concentration of PTHrP-1 to promote ectopic osteogenesis is 0.3 mg/ml. K E Y W O R D S ectopic osteogenesis, PTH-related peptide-1, synthetic peptide, tissue engineering, type I collagen

show abstract

“…A second strategy for improving the regenerative potential of the BMP‐based tissue engineering implants is derived from numerous studies reporting that combinations of BMPs with certain other cytokines can enhance the osteogenic differentiation of progenitor cells in vitro and increase or accelerate bone formation in vivo because of additive or synergistic effects. A great variety of combinations have been tested, especially with mitogenic or angiogenic cytokines such as basic fibroblast growth factor‐2 (FGF‐2), vascular endothelial growth factor (VEGF), or epidermal growth factor (EGF), and most of them resulted in significant improvements compared with the use of single growth factors . Taking this into account, an interesting candidate molecule to improve the collagen‐BMP system for bone regenerative medicine is the insulin‐like growth factor‐1 (IGF‐1), which is a growth‐promoting cytokine that plays an important role in development, metabolism and growth .…”

Section: Introductionmentioning

confidence: 99%

“…A great variety of combinations have been tested, especially with mitogenic or angiogenic cytokines such as basic fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), or epidermal growth factor (EGF), and most of them resulted in significant improvements compared with the use of single growth factors. 14,[17][18][19][20][21] Taking this into account, an interesting candidate molecule to improve the collagen-BMP system for bone regenerative medicine is the insulin-like growth factor-1 (IGF-1), which is a growth-promoting cytokine that plays an important role in development, metabolism and growth. 22 Knockout mice models have shown that IGF-1 deficiencies have strong influence on the normal embryonic and postnatal skeletal development and that the lack of this growth factor produces animals with dwarf phenotype, lower bone formation rates, hypomineralization of the skeleton and abnormal chondrogenesis in the growth plates.…”

Section: Introductionmentioning

confidence: 99%

Insulin‐like growth factor‐1 (IGF‐1) enhances the osteogenic activity of bone morphogenetic protein‐6 (BMP‐6) in vitro and in vivo, and together have a stronger osteogenic effect than when IGF‐1 is combined with BMP‐2

Rico-Llanos

Becerra

Visser

2017

J Biomedical Materials Res

View full text Add to dashboard Cite

Bone morphogenetic protein-2 (BMP-2) is widely used in orthopedic surgery and bone tissue engineering because of its strong osteogenic activity. However, BMP-2 treatments have several drawbacks and many groups are actively exploring alternatives. Since BMP-6 has been demonstrated to be more osteoinductive, its use, either alone or together with other growth factors, might be an interesting option. In this work, we have compared the effect of BMP-2, BMP-6, or insulin-like growth factor-1 (IGF-1), either alone or in combination. Murine preosteoblasts were treated with 15 nM IGF-1 and/or 6 nM BMP-2 or -6 and the expression of osteogenic marker genes, proliferation, and alkaline phosphatase (ALP) activity in vitro were analyzed. The results showed that IGF-1 greatly enhanced the BMP-induced osteogenic differentiation of these cells in general and that the ALP activity in the cultures was higher when the combination was made with BMP-6 than with BMP-2. Furthermore, we tested the osteogenic potential of these treatments in vivo by loading 25 pmoles of IGF-1 and/or 10 pmoles of BMP-2 or -6 onto absorbable collagen sponges and implanting them into an ectopic bone formation model in rats. This study revealed that only BMP-6 was able to induce bone formation at the used dose and that the addition of IGF-1 contributed to an increase of the mineralization in the implants. Hence, the combination of BMP-6 with IGF-1 might be a better alternative than BMP-2 for orthopedic surgery or bone tissue engineering approaches. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 1867-1875, 2017.

show abstract

Osteogenic potential and synergistic effects of growth factors delivered from a bionic composite system

Cited by 6 publications

References 41 publications

Advancements in Hydrogel-Based Drug Sustained Release Systems for Bone Tissue Engineering

Advancements in Hydrogel-Based Drug Sustained Release Systems for Bone Tissue Engineering

Ectopic osteogenesis by type I collagen loaded with a novel synthesized PTH‐related peptide‐1 in vivo

Insulin‐like growth factor‐1 (IGF‐1) enhances the osteogenic activity of bone morphogenetic protein‐6 (BMP‐6) in vitro and in vivo, and together have a stronger osteogenic effect than when IGF‐1 is combined with BMP‐2

Contact Info

Product

Resources

About